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Introduction: Helicobacter pylori (H. pylori) is one of the most common bacterial infections worldwide. The prevalence of Hp infection in cystic
ﬁbrosis (CF) is unclear. Thus, the aim of our study was to determine the prevalence of H. pylori infection in CF patients and to correlate H. pylori
presence with CF expression.
Material and methods: The presence of H. pylori infection was assessed using a breath test with isotope-labeled urea in CF 79 patients compared to
302 healthy control subjects (HS).
Results: Fifteen (19.0%) CF patients were H. pylori positive. No statistical differences in the basic clinical parameters or in their distribution were
documented. No clinical factor was an independent risk factor of H. pylori infection. The corrected prevalence of H. pylori infection in pediatric CF
patients and HS was 14.4% and 9.8%, respectively.
Conclusion: The prevalence of H. pylori infection in CF patients is not different from that in healthy subjects.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Prevalence; Helicobacter pylori; Cystic ﬁbrosis; Epidemiology1. Introduction
Helicobacter pylori (H. pylori) is one of the most common
chronic bacterial infections world-wide [1]. However, the
prevalence of H. pylori infection is not homogeneous. In Western
countries, the prevalence ofH. pylori infection has been decreasing
during the past few decades [2,3]. Nowadays, the prevalence of⁎ Corresponding author. Tel.: +48 61 8480 310; fax: +48 61 8483 362.
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http://dx.doi.org/10.1016/j.jcf.2013.01.004lishedH. pylori infection in European studies varies between 7% in
asymptomatic children in the Czech Republic and 33% in
Northern Norway [4,5]. In Poland, during 2005–2006, H. pylori
infection was diagnosed in 15.7% of children [6]. There was no
difference in the mean age of the infected and the non-infected
children.
H. pylori infection is acquired early in life and in the absence
of antibiotic therapy, it generally persists for life. It is widely
accepted that H. pylori infection is one of the main etiological
factor for gastritis and peptic ulcer disease. Its eradication isby Elsevier B.V. All rights reserved.
Table 1
Clinical and demographic data of CF patients.
Clinical parameters All CF patients Pediatric CF patients
Age [years]
median
(1–3 quartile)
13.6
(8.0–17.2)
10.3
(6.6–15.3)
Sex
Males/females
38/41 29/33
Z-score for body height
median
(1–3 quartile)
−0.84
(−2.21–0.60)
−0.86
(−2.28–0.01)
Z-score for body weight
median
(1–3 quartile)
−0.86
(−1.47 to −0.43)
−0.89
(−1.48 to −0.34)
ALT [U/l]
median
(1–3 quartile)
25.0
(19.0–34.0)
25.5
(19.0–32.2)
AST [U/l]
median
(1–3 quartile)
31.0
(23.0–40.0)
31.0
(24.0–40.2)
INR
median
(1–3 quartile)
1.05
(1.02–1.12)
1.06
(1.02–1.12)
FEV1 [%]
median
(1–3 quartile)
71.5
(47.2–88.5)
72.0
(52.0–95.0)
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Corpus gastritis is associated with a reduction in gastric acid,
multifocal gastric atrophy and an increased risk of gastric cancer
[7–10]. However, there are only few studies assessing prevalence
of H. pylori infection in patients with cystic fibrosis (CF).
Moreover, the results of these studies are sparse and contradictory
[1,11–13].
Przyklenk et al. documented that prevalence of serum IgG
antibodies against H. pylori was the same in CF patients and in
the non-CF group [11]. The authors emphasized that frequency
and length of prophylactic use of antibiotics did not decrease
the prevalence of elevated serum antibodies against H. pylori,
although the majority of antibiotics usually given to CF patients
show a high in vitro activity against H. pylori. On the contrary,
Littlewood et al. found an increased prevalence ofH. pylori in the
CF population [12]. Yahav et al. reported that the prevalence of
H. pylori infection in CF patients (aged 1–44) was lower (16.6%)
than in the age-matched non-CF controls (30.0%) assessing the
H. pylori antigen by using specific monoclonal antibodies in stool
specimens [13]. However, the observed difference was not
statistically significant (p=0.118). Clearly, different tests have
been previously used to determine the prevalence of H. pylori
infections in CF patients. The serum test has been criticized not to
predict an active infection.
2. Aim
The aim of the study was to determine the prevalence of
H. pylori infection in CF patients.
3. Material and methods
The study population consisted of 79 CF patients (38 males &
41 females) 2 to 39 years of age, who did not receive intravenous
or oral antibiotics (with the exception of azithromycin) or proton
pomp inhibitors (PPI) for 3 months prior to the investigation.
The control group consisted of 302 healthy subjects, 3–
18 years of age, who did not receive intravenous or oral antibiotics
or PPIs for four weeks prior to the investigation. The investigation
was part of the project PL0361 “Good diagnosis – treatment –
life” by the First Specialist Clinical Hospital in Zabrze evaluating
the incedences of gastrointestinal diseases in randomly selected
children [14].
The genotypes of the studied CF patients were as follow:
F508del/F508del (n=36), F508del/− (n=14), F508del/2143delT
(n=3), F508del/CFTRdel2,3 (21 kb) (n=2), F508del/2183AANG
(n=3), F508del/3849+10kbcNT (n=2), F508del/1717-1G-A
(n=2), F508del/N1303K (n=1), F508del/3272-26ANG (n=1),
F508del/3659delC (n=1), F508del/G1244E (n=1), F508del/
G542X (n=1), F508del/R553X (n=1), G542X/− (n=2),
N1303K/− (n=1), N1303K/3272-26ANG (n=1), R533X/−
(n=1), 3849+10kbcNT/− (n=1), non detected −/− (n=5) [15].
In all CF patient's Z-score for body height and weight, fecal
elastase-1 concentration, serum alanine aminotransferase (ALT)
and aspartate aminotransferase (AST), International Normalized
Ratio (INR) and frequency of Pseudomonas aeruginosa
(P. aeruginosa) colonization were assessed. FEV1 was determinedin subjects older than 6 years (Table 1). In patients with fecal
elastase-1 concentrations higher than 100 μg/g, fecal fat excretion
was determined to prove pancreatic sufficiency [16,17]. In
addition, the socioeconomic status (urban or rural region) and
genotype of CF patients were assessed.
The presence of H. pylori was assessed in all subjects using
the 13C isotope-labeled urea breath test (UBT). The test was
performed after a minimum fast of 6 h. Two breath samples were
collected as baseline and 30 min after swallowing (drinking) a
200 ml of orange juice drink which contained 50 mg of
13C-labeled urea. To collect the breath samples, 650 ml aluminized
bags connected to one-way valves were used. Measurement of the
13CO2/
12CO2 ratio was carried out using an
13C-infrared isotope
analyser system (IRIS, Wagner Analysen Technik, Bremen,
Germany) with a cut-off value of delta over baseline (DOB)=4‰
[18].
The relationship between clinical status and H. pylori
infection was assessed in all CF patients. The comparison of
the prevalence of H. pylori infection in CF population (n=72)
and healthy age matched subjects is depicted in Table 2.4. Statistical methods
The comparison of the clinical parameters in patients with/
without H. pylori infection was performed using the Mann–
Whitney test. The difference in distribution of the H. pylori
status between groups with different genotypes, with/without
P. aeruginosa colonization, pancreatic sufficiency/insufficien-
cy and socioeconomic status was analyzed by the χ2 test. The
influence of clinical parameters on the presence/absence of
H. pylori infection was determined with the use of the logistic
regression analysis. P value b0.05 was considered statistically
Table 2
Number of children in the age group.
Aged (years) CF patients
(N)
Healthy subjects
(N)
3–6 16 160
7–12 19 136
13–18 27 60
Table 4
H. pylori (Hp) infection and clinical parameters in CF patients.
Clinical parameters Hp positive Hp negative Statistical
significance
Age [years]
median
(1–3 quartile)
14.6
(12.0–19.9)
13.2
(6.8–16.9)
n.s.
Z-score for body height
median
(1–3 quartile)
−0.87
(−2.28 to −0.45)
−0.85
(−2.21–0.08)
n.s.
Z-score for body weight
median
(1–3 quartile)
−0.86
(−2.01 to −0.60)
−0.85
(−1.41 to −0.41)
n.s.
ALT [U/l]
median
(1–3 quartile)
25.0
(17.0–31.0)
25.5
(19.0–35.8)
n.s.
AST [U/l]
median
(1–3 quartile)
30.0
(18.0–41.0)
31.0
(23.3–39.8)
n.s.
INR
median
(1–3 quartile)
1.07
(1.03–1.19)
1.05
(1.01–1.12)
n.s.
FEV1 [%]
median
(1–3 quartile)
75.0
(49.0–89.0)
69.5
(51.0–88.5)
n.s.
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9.0 software.
5. Ethical considerations
The protocol of the investigation was approved by the
Institutional Review Board at Poznan University of Medical
Sciences, Poland.
6. Results
H. pylori infection was diagnosed in 15 out of 79 (19.0%)
CF patients aged 3 to 39 years (Table 3). In the 3 to 18 years
age group a significantly higher percentage (pb0.048) of CF
patients (16.1%) than healthy subjects (9.6%) were H. pylori
positive. However, after the correction for the number of patients
in the age subgroups the prevalence ofH. pylori infection (14.4%
vs 9.8%) did not differ (pb0.173).
No statistical differences in clinical parameters between
H. pylori positive and negative subgroups were detected
(Table 4). The distribution of genotype, P. aeruginosa coloniza-
tion, socioeconomic status (urban v.s. rural region) and pancreatic
sufficiency was comparable in the studied CF subgroups
(Tables 5–7).
In the logistic regression analysis no clinical factor was found
to be an independent risk factor of H. pylori infection.
7. Discussion
There are very few reports on the prevalence of H. pylori
infection in CF patients in the literature [11–13]. Moreover,
H. pylori infection was assessed by an unreliable method
[11] or the group size of CF patients was very small [13].
Therefore, in the present study we assessed a large group of CF
patients using UBT as a gold standard [19] and compared the
results with age matched healthy control subjects.Table 3
Prevalence of H. pylori infection in CF patients and in healthy subjects.
Age H. pylori positive Statistical
significance
CF patients
n (%)
Healthy subjects
n (%)
3–6 0 (0%) 4 (3.7%) 0.810
7–12 4 (21.1%) 16 (11.0%) 0.258
13–18 6 (22.2%) 9 (15.0%) 0.409
All together Raw data 10 (16.1%) 29 (9.6%) 0.048
Corrected value ⁎ 14.4% 9.8% 0.173
⁎ For the number of patients in age subgroups.Serum tests detecting antibodies against H. pylori are not
differentiating between active or previous exposure [20].
H. pylori antibodies were detected in 30.4% of 3435 healthy
Polish children (age 0 to 18 years) [21,22]. Płonka et al. also
found a higher percentage ofH. pylori infection in asymptomatic
children as we did in the present study [23]. 26.0% of healthy
children (age 6 to17), living in urban and 21.6% in rural areas
(Polish Tatra Mountains) had active H. pylori infections as
documented by positive UBTs. Krusiec-Świdergoł et al., found a
similar prevalence of 15.7% H. pylori infection in healthy,
asymptomatic school children (age 7 to 15 years) using the same
method [6]. In the present study, the prevalence of infection in
CF patients was comparable to that of healthy subjects and
independent of their socioeconomic status. Thus, it seems that
prevalence of H. pylori infection in CF patients and healthy
subjects is very similar.
Przyklenk et al. studied 263 CF patients (age 6 months to
34 years) and 168 age matched healthy controls and found a
prevalence of serum IgG H. pylori antibodies in 19.0% and
18.0%, respectively [11]. Yahav et al. reported a prevalence of
H. pylori infection in CF patients and a non-CF control groupTable 5
H. pylori infection and distribution of P. aeruginosa (Pa) colonization, pancreatic
sufficiency and socioeconomic status.
Clinical parameters H. pylori Statistical
significance
Positive
n (%)
Negative
n (%)
Pa colonization Yes 9 (21.5%) 33 (78.5%) n.s.
No 6 (16.2%) 31 (83.8%)
Pancreatic sufficiency Yes 3 (33.3%) 6 (66.7%) n.s.
No 12 (17.2%) 58 (82.8%)
Socioeconomic status Urban 5 (11.9%) 37 (88.1%) n.s.
Rural 10 (27.0%) 27 (73.0%)
Table 6
The prevalence of H. pylori infection in CF patients with different genotypes.
CF mutations H. pylori Statistical significance
Positive
n (%)
Negative
n (%)
Severe/severe 10 (19.6%) 41 (80.4%) n.s.
Others 5 (17.8%) 23 (82.2%)
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detection in stool [13]. Yet, because of the small number of
CF patients (n=30), the observed difference did not reach
statistical significance. In the present study, the prevalence
of H. pylori infection in CF patients (age 3–18 years) was
significantly higher (pb0.048) than in the control group
(16.1% and 9.6%, respectively). However, there were more
CF patients in the older age subgroups. With the correction
for age, the prevalence of H. pylori infection was 14.4% and
9.8%, respectively and thus not any longer statistically significant
(pb0.173).
We did not find any significant relationship between the CF
genotype and H. pylori colonization. However, the manage-
ment of mild and severe CF patients differs and may potentially
have an impact on clearing previous infection. Yahav et al.
noted that prevalence of H. pylori in pancreatic sufficient CF
patients was higher in comparison to patients with pancreatic
insufficiency (75.0% and 7.6%, respectively) [13]. However,
only 4 out of their 30 CF patients were pancreatic sufficient.
The authors suggested that H. pylori infection in CF patients
with pancreatic insufficiency is less frequent because these
patients have a more severe disease form requiring intensive
antibiotic therapy. In addition, H. pylori colonization may have
been reduced due to prolonged secretion of abnormal gastric
mucus which is denser and contains more fructose, galactose,
and N-acetylglucosamine [13,24,25]. Furthermore, we did not
find any statistical difference between pancreatic sufficient and
insufficient patients in the present study. Furthermore, we did not
observe a relationship between the prevalence of P. aeruginosa
colonization and H. pylori infection. Our results are in agreement
with those published by Przyklenk et al. who found a similar
prevalence of chronic P. aeruginosa colonization in H. pylori
positive and negative subgroups [11].
In conclusion, the prevalence of H. pylori infection in CF
patients was not different from that in healthy subjects. There
was no significant relationship between the clinical expression
of disease in CF and H. pylori colonization.Table 7
The prevalence of H. pylori infection in CF patients with F508del and other
mutations.
CF mutations H. pylori Statistical significance
Positive
n (%)
Negative
n (%)
F508del/F508del 7 (19.4%) 29 (80.6%) n.s.
F508del/other 6 (18.7%) 26 (81.3%)
Other genotype 2 (18.2%) 9 (81.8%)Acknowledgments
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